August 23, 2013, I saw this report in Bloomberg Businessweek Technology about AFREZZA, a rapid-acting insulin therapy in the form of a powder that can be breathed in using pre-metered single dose cartridges that plug into an inhaler. Over 5,300 human patients have received treatment using it in 56 different clinical trials. The results when compared to traditional insulin treatment:
- Significant reductions in post-meal glucose fluctuations;
- Comparable overall glucose-level control;
- Lower fasting glucose levels;
- Reduced risk of hypoglycemia;
- Less weight gain.
Costing about the same as conventional insulin injection therapy the FDA is expected to approve AFREZZA’s use sometime in 2014.
Related Posts
Testing AIs With Two Questions Related To Current Events
A New Theory About How Life Originated on Earth and Elsewhere
Can A Universal Influenza Vaccine End Seasonal Flu Forever?
I Had Knee Replacement Surgery in 2020 But Could 3D Bioprinting Do The Job In The Future?
Decarbonizing Diesel Means Cleaner Fuel and Greener Engine Technology
Electrified Thermochemical Reactor Could Revolutionize and Decarbonize Heavy Industry
Satellite Monitoring Revolutionizes 21st Century Agricultural Practices
Ask Voters What’s Most Important To Them And Climate Change Seldom Gets Mentioned
